KAHR Medical ("KAHR") is an Immuno-Oncology drug development company. Harnessing the power of the TNF Superfamily (regulators of the immune system) for treatment of disease.
KAHR is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment options for cancer and autoimmune disorders.
KAHR’s drug development pipeline is built around the 'Dual Signaling Proteins' (DSP) technology, also known as 'Signal Converter Proteins' (SCP), the outgrowth of research carried out for more than 15 years at the University of Pennsylvania and the Hadassah Medical Center. The results of these research efforts have been published in many scientific publications.
The enhanced architecture of DSP molecules creates fusion-proteins with two functional ends. This structure allows the chimeric (fused) DSP molecule to possess two biologically active ends, facilitating a unique mode-of-action in which two reinforcing signals drive increased activity, specificity and therapeutic benefits that cannot be achieved by simply administering the DSP protein elements as separate units.
DSP molecules are mostly constructed around the TNF-superfamily, the family of factors that manage our immune system, and are especially effective in targeting complex biological processes within the immune system. The DSP technology is split into two drug platforms; DSP-Hexamers and DSP-Clusters, both proprietary platforms cover hundreds of drug candidates. KAHR Medical promises to significantly extend the repertoire of protein pharmaceuticals available for cancer and autoimmune patients, and is currently developing two DSP drug candidates towards clinical trials; KAHR-101, a DSP-Cluster forming drug and KAHR-102, a DSP-Hexamer forming product. Both lead products are potential drugs for the treatment of multiple cancer indications and autoimmune diseases. KAHR plans to initially assess both KAHR-101 and KAHR-102 in clinical trials for the treatment of cancer.